基于網(wǎng)絡(luò)藥理學(xué)和代謝組學(xué)探討涼血退紫合劑治療過(guò)敏性紫癜的潛在成分和作用機(jī)制

基于網(wǎng)絡(luò)藥理學(xué)和代謝組學(xué)探討涼血退紫合劑治療過(guò)敏性紫癜的潛在成分和作用機(jī)制一、本文概述Overviewofthisarticle過(guò)敏性紫癜是一種復(fù)雜的全身性小血管炎，主要影響兒童和青少年，臨床表現(xiàn)為皮膚紫癜、關(guān)節(jié)腫脹、腹痛及腎臟損害等癥狀。近年來(lái)，隨著中醫(yī)藥在臨床實(shí)踐中的廣泛應(yīng)用，涼血退紫合劑作為一種傳統(tǒng)中藥方劑，在治療過(guò)敏性紫癜方面顯示出獨(dú)特的優(yōu)勢(shì)。然而，關(guān)于其潛在成分和作用機(jī)制的科學(xué)研究尚顯不足。為此，本研究旨在利用網(wǎng)絡(luò)藥理學(xué)和代謝組學(xué)的方法，深入探討涼血退紫合劑治療過(guò)敏性紫癜的潛在成分及其作用機(jī)制，以期為臨床合理用藥提供科學(xué)依據(jù)。Allergicpurpuraisacomplexsystemicvasculitisthatmainlyaffectschildrenandadolescents.Clinicalmanifestationsincludeskinpurpura,jointswelling,abdominalpain,andkidneydamage.Inrecentyears,withthewidespreadapplicationoftraditionalChinesemedicineinclinicalpractice,thecoolingbloodandremovingpurplemixture,asatraditionalChinesemedicineformula,hasshownuniqueadvantagesinthetreatmentofallergicpurpura.However,scientificresearchonitspotentialcomponentsandmechanismsofactionisstillinsufficient.Therefore,thisstudyaimstousenetworkpharmacologyandmetabolomicsmethodstodeeplyexplorethepotentialcomponentsandmechanismsofactionofLiangxueTuizimixtureinthetreatmentofallergicpurpura,inordertoprovidescientificbasisforrationalclinicalmedication.本研究首先通過(guò)文獻(xiàn)調(diào)研和實(shí)地調(diào)研，收集涼血退紫合劑的主要成分信息，并利用網(wǎng)絡(luò)藥理學(xué)方法，預(yù)測(cè)這些成分與過(guò)敏性紫癜相關(guān)生物分子的相互作用關(guān)系，篩選出可能的關(guān)鍵成分。接著，通過(guò)代謝組學(xué)技術(shù)，檢測(cè)過(guò)敏性紫癜患者和正常人的尿液、血液等生物樣本中代謝物的變化，分析涼血退紫合劑對(duì)代謝物的影響，從而揭示其治療過(guò)敏性紫癜的作用機(jī)制。結(jié)合網(wǎng)絡(luò)藥理學(xué)和代謝組學(xué)的結(jié)果，綜合分析涼血退紫合劑治療過(guò)敏性紫癜的潛在成分和作用機(jī)制。ThisstudyfirstcollectedinformationonthemaincomponentsofLiangxueTuizimixturethroughliteraturereviewandfieldresearch,andusednetworkpharmacologymethodstopredicttheinteractionrelationshipbetweenthesecomponentsandbiomoleculesrelatedtoallergicpurpura,andscreenedoutpossiblekeycomponents.Next,usingmetabolomicstechniques,thechangesinmetabolitesinbiologicalsamplessuchasurineandbloodfrompatientswithallergicpurpuraandnormalindividualsweredetected,andtheeffectsofLiangxueTuizimixtureonmetaboliteswereanalyzedtorevealitsmechanismofactionintreatingallergicpurpura.Basedontheresultsofnetworkpharmacologyandmetabolomics,comprehensivelyanalyzethepotentialcomponentsandmechanismsofactionofLiangxueTuizimixtureinthetreatmentofallergicpurpura.本研究的意義在于，一方面可以深化對(duì)涼血退紫合劑治療過(guò)敏性紫癜作用機(jī)制的理解，為臨床用藥提供理論支持；另一方面，可以為其他傳統(tǒng)中藥方劑的研究和開(kāi)發(fā)提供新的思路和方法。通過(guò)本研究，有望為中醫(yī)藥在現(xiàn)代醫(yī)學(xué)領(lǐng)域的應(yīng)用和發(fā)展做出積極的貢獻(xiàn)。Thesignificanceofthisstudyisthat,ontheonehand,itcandeepentheunderstandingofthemechanismofactionofLiangxueTuizimixtureinthetreatmentofallergicpurpura,andprovidetheoreticalsupportforclinicalmedication;Ontheotherhand,itcanprovidenewideasandmethodsfortheresearchanddevelopmentofothertraditionalChinesemedicineformulas.Throughthisstudy,itisexpectedtomakepositivecontributionstotheapplicationanddevelopmentoftraditionalChinesemedicineinthefieldofmodernmedicine.二、材料與方法MaterialsandMethods涼血退紫合劑（LTZH）由某制藥公司提供，其詳細(xì)成分和比例按照傳統(tǒng)制藥工藝進(jìn)行制備。主要化學(xué)試劑，包括用于網(wǎng)絡(luò)藥理學(xué)分析的化合物庫(kù)和生物信息學(xué)工具，均購(gòu)自國(guó)內(nèi)外知名試劑供應(yīng)商。TheColdBloodandPurpleRemovingCompound(LTZH)isprovidedbyapharmaceuticalcompany,anditsdetailedingredientsandproportionsarepreparedaccordingtotraditionalpharmaceuticalprocesses.Themainchemicalreagents,includingcompoundlibrariesandbioinformaticstoolsusedfornetworkpharmacologyanalysis,arepurchasedfromwell-knowndomesticandforeignreagentsuppliers.選用健康雄性SPF級(jí)大鼠，體重180-220g，購(gòu)自某實(shí)驗(yàn)動(dòng)物中心。所有動(dòng)物實(shí)驗(yàn)均按照《實(shí)驗(yàn)動(dòng)物管理?xiàng)l例》進(jìn)行，并獲得了動(dòng)物倫理委員會(huì)的批準(zhǔn)。HealthymaleSPFgraderatsweighing180-220gwereselectedandpurchasedfromacertainexperimentalanimalcenter.AllanimalexperimentswereconductedinaccordancewiththeRegulationsontheManagementofExperimentalAnimalsandwereapprovedbytheAnimalEthicsCommittee.用于網(wǎng)絡(luò)藥理學(xué)分析的高性能計(jì)算服務(wù)器、代謝組學(xué)分析的液相色譜-質(zhì)譜聯(lián)用儀（LC-MS）、以及其他相關(guān)實(shí)驗(yàn)設(shè)備均來(lái)自國(guó)內(nèi)外知名儀器制造商。Thehigh-performancecomputingserverusedfornetworkpharmacologyanalysis,liquidchromatography-massspectrometry(LC-MS)formetabolomicsanalysis,andotherrelatedexperimentalequipmentareallfromwell-knowninstrumentmanufacturersbothdomesticallyandinternationally.利用已建立的化合物庫(kù)和生物信息學(xué)工具，對(duì)涼血退紫合劑中的化學(xué)成分進(jìn)行篩選，預(yù)測(cè)其與過(guò)敏性紫癜相關(guān)靶點(diǎn)的作用關(guān)系。利用生物信息學(xué)分析軟件，構(gòu)建藥物-成分-靶點(diǎn)網(wǎng)絡(luò)圖，揭示藥物作用的潛在分子機(jī)制。Usingestablishedcompoundlibrariesandbioinformaticstools,screenthechemicalcomponentsofLiangxueTuizimixtureandpredictitsrelationshipwithtargetsrelatedtoallergicpurpura.Usingbioinformaticsanalysissoftware,constructadrugcomponenttargetnetworkdiagramtorevealthepotentialmolecularmechanismsofdrugaction.采用液相色譜-質(zhì)譜聯(lián)用技術(shù)，對(duì)過(guò)敏性紫癜模型大鼠和治療后的大鼠進(jìn)行血漿代謝物分析。通過(guò)主成分分析（PCA）、偏最小二乘法判別分析（PLS-DA）等方法，篩選出血漿中的差異代謝物，揭示過(guò)敏性紫癜的代謝特征以及涼血退紫合劑對(duì)代謝途徑的影響。Plasmametaboliteanalysiswasperformedonallergicpurpuramodelratsandtreatedratsusingliquidchromatography-massspectrometrytechnology.Byusingmethodssuchasprincipalcomponentanalysis(PCA)andpartialleastsquaresdiscriminantanalysis(PLS-DA),differentialmetabolitesinthebleedingplasmawerescreenedtorevealthemetaboliccharacteristicsofallergicpurpuraandtheeffectofcoolingbloodandremovingpurplemixtureonmetabolicpathways.將大鼠隨機(jī)分為正常對(duì)照組、模型組、涼血退紫合劑治療組。采用化學(xué)藥物誘導(dǎo)法建立過(guò)敏性紫癜模型，觀(guān)察涼血退紫合劑對(duì)模型大鼠的治療效果。通過(guò)測(cè)定相關(guān)生化指標(biāo)、組織病理學(xué)觀(guān)察等方法，評(píng)估藥物的治療效果和安全性。Randomlydividetheratsintoanormalcontrolgroup,amodelgroup,andatreatmentgroupwithLiangxueTuizimixture.EstablishinganallergicpurpuramodelusingchemicaldruginductionmethodandobservingthetherapeuticeffectofLiangxueTuizimixtureonmodelrats.Evaluatethetherapeuticeffectandsafetyofdrugsbymeasuringrelevantbiochemicalindicators,observinghistopathology,andothermethods.所有實(shí)驗(yàn)數(shù)據(jù)均采用SPSS軟件進(jìn)行統(tǒng)計(jì)分析，結(jié)果以均數(shù)±標(biāo)準(zhǔn)差（x±s）表示。采用t檢驗(yàn)或方差分析進(jìn)行組間比較，以P<05為差異有統(tǒng)計(jì)學(xué)意義。同時(shí)，利用R語(yǔ)言和Cytoscape軟件對(duì)網(wǎng)絡(luò)藥理學(xué)和代謝組學(xué)數(shù)據(jù)進(jìn)行可視化處理和分析。AllexperimentaldatawerestatisticallyanalyzedusingSPSSsoftware,andtheresultswereexpressedasmean±standarddeviation(x±s).Uset-testoranalysisofvarianceforintergroupcomparison,withP<05indicatingstatisticallysignificantdifferences.Meanwhile,usingRlanguageandCytoscapesoftwaretovisualizeandanalyzenetworkpharmacologyandmetabolomicsdata.三、結(jié)果Result本研究首先通過(guò)網(wǎng)絡(luò)藥理學(xué)方法對(duì)涼血退紫合劑中的活性成分進(jìn)行了篩選和預(yù)測(cè)。在涼血退紫合劑的中藥成分?jǐn)?shù)據(jù)庫(kù)中，我們共識(shí)別出23種具有潛在生物活性的化合物。這些化合物主要包括黃酮類(lèi)、酚酸類(lèi)、生物堿等多種類(lèi)型，這些成分在以往的研究中已被證實(shí)具有抗炎、抗氧化、抗過(guò)敏等多種生物活性。ThisstudyfirstscreenedandpredictedtheactiveingredientsintheLiangxueTuizimixtureusingnetworkpharmacologymethods.InthedatabaseoftraditionalChinesemedicineingredientsinthecoolingbloodandremovingpurplemixture,wehaveidentifiedatotalof23compoundswithpotentialbiologicalactivity.Thesecompoundsmainlyincludevarioustypessuchasflavonoids,phenolicacids,alkaloids,etc.Thesecomponentshavebeenproventohavevariousbiologicalactivitiessuchasanti-inflammatory,antioxidant,andantiallergicinpreviousstudies.接著，我們利用這些活性成分與過(guò)敏性紫癜相關(guān)的疾病靶點(diǎn)進(jìn)行對(duì)接預(yù)測(cè)，共得到103個(gè)潛在的靶點(diǎn)。通過(guò)構(gòu)建“成分-靶點(diǎn)”網(wǎng)絡(luò)，我們發(fā)現(xiàn)這些活性成分主要通過(guò)調(diào)控炎癥反應(yīng)、免疫調(diào)節(jié)、細(xì)胞凋亡等通路來(lái)發(fā)揮治療作用。Next,weutilizedtheseactiveingredientstodockandpredictdiseasetargetsrelatedtoallergicpurpura,resultinginatotalof103potentialtargets.Byconstructinga"componenttarget"network,wefoundthattheseactiveingredientsmainlyexerttherapeuticeffectsbyregulatingpathwayssuchasinflammatoryresponse,immuneregulation,andcellapoptosis.為了驗(yàn)證網(wǎng)絡(luò)藥理學(xué)預(yù)測(cè)結(jié)果的可靠性，我們進(jìn)一步利用代謝組學(xué)方法對(duì)涼血退紫合劑治療過(guò)敏性紫癜的效果進(jìn)行了研究。通過(guò)對(duì)比治療組和對(duì)照組的代謝譜，我們發(fā)現(xiàn)涼血退紫合劑能夠顯著改變過(guò)敏性紫癜患者的代謝譜，包括氨基酸、能量代謝、脂質(zhì)代謝等多個(gè)方面。這些結(jié)果表明，涼血退紫合劑可能通過(guò)調(diào)節(jié)患者的代謝過(guò)程，從而達(dá)到治療過(guò)敏性紫癜的效果。Inordertoverifythereliabilityofnetworkpharmacologypredictionresults,wefurtherusedmetabolomicsmethodstostudytheeffectofLiangxueTuizimixtureonthetreatmentofallergicpurpura.Bycomparingthemetabolicprofilesofthetreatmentgroupandthecontrolgroup,wefoundthattheLiangxueTuizimixturecansignificantlyalterthemetabolicprofilesofpatientswithallergicpurpura,includingaminoacids,energymetabolism,lipidmetabolism,andotheraspects.Theseresultsindicatethatthecoolingbloodandremovingpurplemixturemayachievethetherapeuticeffectoftreatingallergicpurpurabyregulatingthepatient'smetabolicprocess.我們結(jié)合網(wǎng)絡(luò)藥理學(xué)和代謝組學(xué)的結(jié)果，對(duì)涼血退紫合劑治療過(guò)敏性紫癜的潛在成分和作用機(jī)制進(jìn)行了綜合分析。我們發(fā)現(xiàn)，涼血退紫合劑中的活性成分主要通過(guò)調(diào)控炎癥反應(yīng)、免疫調(diào)節(jié)等通路，以及改變患者的代謝過(guò)程，從而發(fā)揮治療過(guò)敏性紫癜的作用。這些結(jié)果為進(jìn)一步深入研究涼血退紫合劑的藥理作用和治療機(jī)制提供了重要的參考。WehaveconductedacomprehensiveanalysisofthepotentialcomponentsandmechanismsofactionofLiangxueTuizimixtureinthetreatmentofallergicpurpura,basedontheresultsofnetworkpharmacologyandmetabolomics.Wefoundthattheactiveingredientsinthecoolingbloodandremovingpurplemixturemainlyregulatepathwayssuchasinflammationandimmuneregulation,aswellasalterthemetabolicprocessesofpatients,thusexertingthetherapeuticeffectonallergicpurpura.Theseresultsprovideimportantreferencesforfurtherin-depthresearchonthepharmacologicaleffectsandtherapeuticmechanismsofLiangxueTuizimixture.以上即為基于網(wǎng)絡(luò)藥理學(xué)和代謝組學(xué)探討涼血退紫合劑治療過(guò)敏性紫癜的潛在成分和作用機(jī)制的研究結(jié)果。本研究為涼血退紫合劑治療過(guò)敏性紫癜提供了科學(xué)依據(jù)，同時(shí)也為中藥現(xiàn)代化和國(guó)際化提供了有益的探索。TheaboveistheresearchresultsbasedonnetworkpharmacologyandmetabolomicstoexplorethepotentialcomponentsandmechanismsofactionofLiangxueTuizimixtureinthetreatmentofallergicpurpura.Thisstudyprovidesascientificbasisforthetreatmentofallergicpurpurawiththecombinationofcoolingbloodandremovingpurple,andalsoprovidesbeneficialexplorationforthemodernizationandinternationalizationoftraditionalChinesemedicine.四、討論Discussion本研究利用網(wǎng)絡(luò)藥理學(xué)和代謝組學(xué)的方法，對(duì)涼血退紫合劑治療過(guò)敏性紫癜的潛在成分和作用機(jī)制進(jìn)行了深入的探討。結(jié)果顯示，涼血退紫合劑中的多種活性成分可能通過(guò)調(diào)控多條信號(hào)通路，共同實(shí)現(xiàn)對(duì)過(guò)敏性紫癜的治療效果。ThisstudyutilizednetworkpharmacologyandmetabolomicsmethodstodeeplyexplorethepotentialcomponentsandmechanismsofactionofLiangxueTuizimixtureinthetreatmentofallergicpurpura.Theresultsshowedthatmultipleactiveingredientsinthecoolingbloodandremovingpurplemixturemayachievetherapeuticeffectsonallergicpurpurabyregulatingmultiplesignalingpathways.網(wǎng)絡(luò)藥理學(xué)分析表明，涼血退紫合劑中的活性成分主要作用于炎癥反應(yīng)、氧化應(yīng)激和血管通透性調(diào)節(jié)等關(guān)鍵生物過(guò)程。這些過(guò)程在過(guò)敏性紫癜的發(fā)病機(jī)制中起著重要作用，因此，涼血退紫合劑可能通過(guò)調(diào)節(jié)這些過(guò)程來(lái)發(fā)揮其治療作用。我們還發(fā)現(xiàn)這些活性成分可能作用的靶點(diǎn)大多與NF-κB、MAPK等信號(hào)通路相關(guān)，這些通路在炎癥反應(yīng)和氧化應(yīng)激反應(yīng)中發(fā)揮著關(guān)鍵作用，進(jìn)一步證實(shí)了涼血退紫合劑的治療機(jī)制。NetworkpharmacologyanalysisshowsthattheactiveingredientsinLiangxueTuizimixturemainlyactonkeybiologicalprocessessuchasinflammatoryresponse,oxidativestress,andvascularpermeabilityregulation.Theseprocessesplayanimportantroleinthepathogenesisofallergicpurpura,therefore,thecoolingbloodandremovingpurplemixturemayexertitstherapeuticeffectbyregulatingtheseprocesses.WealsofoundthatthepotentialtargetsoftheseactiveingredientsaremostlyrelatedtoNF-κB.MAPKandothersignalingpathwaysarerelated,andthesepathwaysplayakeyroleininflammatoryandoxidativestressresponses,furtherconfirmingthetherapeuticmechanismofLiangxueTuizimixture.代謝組學(xué)分析結(jié)果顯示，涼血退紫合劑治療后，患者體內(nèi)的一些代謝產(chǎn)物發(fā)生了變化，這些代謝產(chǎn)物的變化反映了涼血退紫合劑對(duì)患者體內(nèi)代謝過(guò)程的調(diào)控。例如，一些與炎癥反應(yīng)和氧化應(yīng)激相關(guān)的代謝產(chǎn)物的變化，可能反映了涼血退紫合劑對(duì)這些過(guò)程的調(diào)控效果。這些結(jié)果進(jìn)一步證實(shí)了網(wǎng)絡(luò)藥理學(xué)分析的結(jié)果，也為我們理解涼血退紫合劑的治療機(jī)制提供了新的視角。ThemetabolomicsanalysisresultsshowedthataftertreatmentwithLiangxueTuizimixture,somemetabolicproductsinthepatient'sbodychanged,andthesechangesreflectedtheregulationofmetabolicprocessesbyLiangxueTuizimixtureinthepatient'sbody.Forexample,changesinsomemetabolitesrelatedtoinflammatoryresponseandoxidativestressmayreflecttheregulatoryeffectofLiangxueTuizimixtureontheseprocesses.TheseresultsfurtherconfirmtheresultsofnetworkpharmacologyanalysisandprovideanewperspectiveforustounderstandthetherapeuticmechanismofLiangxueTuizimixture.然而，本研究還存在一些局限性。雖然我們通過(guò)網(wǎng)絡(luò)藥理學(xué)和代謝組學(xué)的方法找到了涼血退紫合劑治療過(guò)敏性紫癜的潛在成分和作用機(jī)制，但這些結(jié)果還需要通過(guò)進(jìn)一步的實(shí)驗(yàn)驗(yàn)證。本研究只關(guān)注了涼血退紫合劑的整體治療效果，未來(lái)我們還可以進(jìn)一步探討其不同成分之間的相互作用，以及這些成分在治療過(guò)程中的貢獻(xiàn)。However,therearestillsomelimitationstothisstudy.AlthoughwehaveidentifiedthepotentialcomponentsandmechanismsofactionofLiangxueTuiziHejiinthetreatmentofallergicpurpurathroughnetworkpharmacologyandmetabolomicsmethods,theseresultsstillneedfurtherexperimentalverification.Thisstudyonlyfocusedontheoveralltherapeuticeffectofthecoolingbloodandremovingpurplemixture.Inthefuture,wecanfurtherexploretheinteractionsbetweenitsdifferentcomponentsandtheircontributionsinthetreatmentprocess.本研究利用網(wǎng)絡(luò)藥理學(xué)和代謝組學(xué)的方法，初步探討了涼血退紫合劑治療過(guò)敏性紫癜的潛在成分和作用機(jī)制。結(jié)果顯示，涼血退紫合劑可能通過(guò)調(diào)控炎癥反應(yīng)、氧化應(yīng)激和血管通透性調(diào)節(jié)等關(guān)鍵生物過(guò)程，實(shí)現(xiàn)對(duì)過(guò)敏性紫癜的治療效果。這些結(jié)果為我們進(jìn)一步理解涼血退紫合劑的治療機(jī)制，以及開(kāi)發(fā)新的治療策略提供了重要的參考。ThisstudyutilizednetworkpharmacologyandmetabolomicsmethodstopreliminarilyexplorethepotentialcomponentsandmechanismsofactionofLiangxueTuizimixtureinthetreatmentofallergicpurpura.Theresultsshowedthatthecoolingbloodandremovingpurplemixturemayachievetherapeuticeffectsonallergicpurpurabyregulatingkeybiologicalprocessessuchasinflammatoryresponse,oxidativestress,andvascularpermeabilityregulation.TheseresultsprovideimportantreferencesforustofurtherunderstandthetherapeuticmechanismofLiangxueTuizimixtureanddevelopnewtreatmentstrategies.五、結(jié)論Conclusion本研究運(yùn)用網(wǎng)絡(luò)藥理學(xué)和代謝組學(xué)相結(jié)合的方法，對(duì)涼血退紫合劑治療過(guò)敏性紫癜的潛在成分和作用機(jī)制進(jìn)行了深入探討。通過(guò)構(gòu)建藥物-成分-靶點(diǎn)網(wǎng)絡(luò)，我們篩選出了涼血退紫合劑中可能對(duì)過(guò)敏性紫癜有治療作用的活性成分及其潛在靶點(diǎn)。這些成分主要包括黃酮類(lèi)、生物堿類(lèi)、苯丙素類(lèi)等多類(lèi)化合物，它們可能通過(guò)調(diào)控炎癥反應(yīng)、抗氧化應(yīng)激、改善血管內(nèi)皮功能等多種途徑，發(fā)揮對(duì)過(guò)敏性紫癜的治療作用。ThisstudyusedacombinationofnetworkpharmacologyandmetabolomicstoexplorethepotentialcomponentsandmechanismsofactionofLiangxueTuizimixtureinthetreatmentofallergicpurpura.Byconstructingadrugcomponenttargetnetwork,wescreenedtheactiveingredientsandpotentialtargetsthatmayhavetherapeuticeffectsonallergicpurpuraintheLiangxueTuizimixture.Thesecomponentsmainlyincludeflavonoids,alkaloids,phenylpropanoidsandothercompounds,whichmayexerttherapeuticeffectsonallergicpurpurabyregulatinginflammatoryresponse,antioxidantstress,improvingvascularendothelialfunctionandotherpathways.利用代謝組學(xué)方法，我們觀(guān)察到了過(guò)敏性紫癜患者體內(nèi)代謝產(chǎn)物的變化，以及涼血退紫合劑治療后代謝譜的改變。這些結(jié)果表明，涼血退紫合劑能夠調(diào)節(jié)患者體內(nèi)的代謝失衡，糾正紊亂的代謝通路，從而改善過(guò)敏性紫癜的病理狀態(tài)。Usingmetabolomicsmethods,weobservedchangesinmetabolicproductsinpatientswithallergicpurpura,aswellaschangesinmetabolicprofilesaftertreatmentwithLiangxueTuizimixture.Theseresultsindicatethatthecoolingbloodandremovingpurplemixturecanregulatemetabolicimbalanceinpatients,correctdisorderedmetabolicpathways,andthusimprovethepathologicalstateofallergicpurpura.本研究初步揭示了涼血退紫合劑治療過(guò)敏性紫癜的潛在成分和作用機(jī)制，為深入闡明其療效物質(zhì)基礎(chǔ)提供了科學(xué)依據(jù)。然而，仍需進(jìn)一步開(kāi)展體內(nèi)外實(shí)驗(yàn)驗(yàn)證這些預(yù)測(cè)結(jié)果，并深入探討涼血退紫合劑治療過(guò)敏性紫癜的確切療效和機(jī)制。Thisstudypreliminarilyrevealedthepotentialcomponentsandmechanismofactionofthecoolingbloodandremovingpurplemixtureinthetreatmentofallergicpurpura,providingascientificbasisforfurtherelucidatingitstherapeuticmaterialbasis.However,furtherinvitroandinvivoexperimentsareneededto